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Abstract: Cerebral palsy is an important health issue that has a strong socioeconomic 
impact. There is no cure for cerebral palsy, and therapeutic approaches only report small 
  benefits for affected people. In this study we assessed the effects of growth hormone treatment 
(0.3 µg/kg/day) combined with physical rehabilitation in the recovery of gross motor function 
in children with growth hormone deficiency and cerebral palsy (four males and six females, 
mean age 5.63 ± 2.32 years) as compared with that observed in a similar population of cerebral 
palsy children (five males, five females, mean age 5.9 ± 2.18 years) without growth hormone 
deficiency treated only with physical rehabilitation for two months. The Gross Motor Function 
Measure (GMFM-88) and Modified Ashworth Scale were performed before commencing the 
treatment and after completion thereof. In children with cerebral palsy and growth hormone 
deficiency, Dimension A (P , 0.02), dimension B (P , 0.02), and dimension C (P , 0.02) 
of the GMFM-88, and the total score of the test (P , 0.01) significantly improved after the 
treatment; dimension D and dimension E did not increase, and four of five spastic patients 
showed a reduction in spasticity. However, in children with cerebral palsy and without growth 
hormone deficiency, only the total score of the test improved significantly after the treatment 
period. This indicates that growth hormone replacement therapy was responsible for the large 
differences observed between both groups in response to physical rehabilitation. We propose 
that the combined therapy involving growth hormone administration and physical rehabilitation 
may be a useful therapeutic approach in the recovery of gross motor function in children with 
growth hormone deficiency and cerebral palsy.
Keywords: growth hormone, cerebral palsy, neural plasticity, neural regeneration, physical 
rehabilitation, gross motor function
Introduction
Cerebral palsy describes a group of disorders of the development of movement and 
posture, causing activity limitation, that are attributed to nonprogressive disturbances 
that occurred in the developing fetal or infant brain. The motor disorders of cerebral 
palsy are often accompanied by disturbances of sensation, cognition, communica-
tion, perception, and/or behavior, and/or by a seizure disorder.1 Cerebral palsy is the 
most common cause of physical disability in childhood.2 The estimated prevalence of 
cerebral palsy in the general population is 2/1000,3 and the cumulative incidence rate 
of cerebral palsy in the age group 5–7 years is 2.7/1000.3 Major causes of cerebral 
palsy involve prematurity (40%–50% of cases), abnormal intrauterine development Therapeutics and Clinical Risk Management 2010:6 submit your manuscript | www.dovepress.com
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due to fetal-maternal infections, asphyxia during delivery, 
brain trauma during labor and delivery, and complications in 
the perinatal period.4 Independent of causal factors respon-
sible for the development of cerebral palsy, the disease has 
a strong socioeconomic impact.5 Currently there is no cure 
for cerebral palsy, and the therapeutic approaches of physical 
therapy, occupational therapy, speech therapy, neuropsychol-
ogy, pharmacology, and surgery achieve only partial benefits 
for affected individuals.3
It has been shown that children with cerebral palsy often 
have poor linear growth during childhood, resulting in a 
diminished final adult height,6 an issue that has received 
little attention so far.6–10 In the studies that have been 
reported, the investigators have demonstrated that children 
with cerebral palsy show cerebral palsy deficient growth 
hormone secretion, by using provocative tests for growth 
hormone, that insulin-like growth factor (IGF-1) and low 
growth hormone levels in children with cerebral palsy may 
explain their low height and that decreased plasma IGF-1 and 
IGF binding protein 3 (IGFBP3) levels are associated with 
osteopenia in children with cerebral palsy.6–10 We have previ-
ously shown that 70% of a population of 46 children with 
cerebral palsy lacked normal growth hormone secretion.3 
Among the phenomena that could cause impaired growth 
hormone secretion are the presence of an altered pool of 
neurotransmitters, psychosocial deprivation, or suboptimal 
nutritional status.3
Neural plasticity and regeneration of the brain, in response 
to both neurologic injury and different neurological stimula-
tions have been widely demonstrated in animal models11–14 
and in clinical studies using imaging techniques,15–18 electro-
physiologic assessments,19,20 and clinical tests.21–25 Moreover, 
it has been reported that the mechanisms of plasticity are 
increased in the developing central nervous system, so that 
children who suffer injury at this stage could achieve more 
complete recovery than adult patients.26
Several hormones play a role in the recovery from 
brain injuries, acting either on neurogenesis and/or neural 
plasticity. Among these, the growth hormone-IGF-1 sys-
tem seems to be very important for inducing adult neuro-
genesis and increasing brain plasticity.3 Growth hormone 
and IGF-1 and their receptors are expressed locally in the 
brain27–36 and both hormones can cross the blood–brain 
  barrier.36 Thus, besides its role in several metabolic 
processes, it has been shown that the growth hormone-
IGF-1 axis exerts multiple and important neurotrophic 
effects related to cell proliferation and survival, both in 
the   central and peripheral nervous system.3,36 In fact, a 
number of studies have   demonstrated that this endocrine 
axis induces strong proliferation of neural cell precursors 
in major neurogenic niches, under both physiologic and 
pathologic conditions.35,37–39 Moreover, growth hormone 
expression is increased in the affected brain hemisphere 
after an ischemic injury.40,41 On the other hand, we dem-
onstrated, for the first time, that growth hormone is an 
important factor for cell survival.42 Thus, both growth 
hormone and IGF-1 display marked neuroprotective43,44 
and antiapoptotic45–47 effects.
In a previous study we postulated that growth hormone 
replacement therapy might be useful in the treatment of 
children with cerebral palsy, not only for achieving a more 
normal height but also for correcting some of the neurologic 
disorders that these patients suffer.3 This study was designed 
to test this hypothesis, and evaluated the effects of growth 
hormone treatment combined with physical rehabilitation in 
the recovery of gross motor function in children with growth 
hormone deficiency and cerebral palsy as compared with 
the effects obtained in a similar population of cerebral palsy 
children without growth hormone deficiency and treated only 
with physical rehabilitation. Despite the fact that exercise is 
a powerful stimulus for pituitary growth hormone secretion, 
cerebral palsy children without growth hormone deficiency 
subjected to intense physical therapy rehabilitation do not 
achieve significant improvements. We studied the effects of 
growth hormone therapy in children with cerebral palsy and 
growth hormone deficiency as compared with those obtained 
in children with cerebral palsy and without growth hormone 
deficiency subjected to the same physical rehabilitation. The 
rationale for this was to test whether or not exogenous growth 
hormone administration plays a role in neurogenesis and/or 
brain plasticity.
Method
Participants
The study was conducted in 20 children with cerebral palsy, 
comprising nine males and 11 females, aged 4.0–10.5 years, 
who attended the Medical Center Proyecto Foltra for physi-
cal and cognitive rehabilitation, selected from a population 
of 46 cerebral palsy children.3 The reason for selecting 
20 children from 46 was to achieve the best possible match 
between the groups with regard to age, gender, disabilities 
exhibited, and clinical history. The selection was made by 
the principal investigator, and none of the therapists knew 
whether or not the children selected had growth hormone 
deficiency. All patients were Level IV or V according to 
the Gross Motor Function Classification System.48 Ten of Therapeutics and Clinical Risk Management 2010:6 submit your manuscript | www.dovepress.com
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these cerebral palsy children had been previously detected to 
have growth hormone deficiency,3 and comprised the study 
group. The main characteristics of the patients in each group 
studied are shown in Tables 1 and 2.
Treatment of growth hormone deficiency
After obtaining informed consent from their parents, the 
children with cerebral palsy and growth hormone deficiency 
were given growth hormone (rhGH, Omnitrope®, Sandoz) 
0.3 µg/kg/day subcutaneously for five days per week at 10.30 
pm for two months). Growth hormone administration com-
menced when physical rehabilitation started.
Blood sample analyses was performed for routine 
hematology and biochemistry parameters. Baseline anterior 
pituitary hormone secretion and plasma levels of free T4 
were measured by chemiluminescence assays. In addi-
tion, fasting plasma IGF-1 and IGFBP3 were measured 
by solid-phase, enzyme-labeled chemiluminescent immu-
nometric assay (Inmulite 2000, Siemens). These analyses 
were carried out before commencing the study and at the 
end of the study.
Clinical assessment
To assess motor function in our patients, we used a widely 
recognized test, the Gross Motor Function Measure (GMFM-
88).49 The GMFM-88 is a scale constructed for evaluation 
of change in gross motor function in children with cerebral 
palsy. The GMFM-88 consists of 88 items grouped into five 
dimensions, ie, dimension A (lying and rolling, 17 items), 
dimension B (sitting, 20 items), dimension C (crawling and 
kneeling, 14 items), dimension D (standing, 13 items) and 
dimension E (walking, running, and jumping, 24 items). 
Scores for each dimension are expressed as a percentage of 
the maximum score for that dimension, adding the scores 
for all dimensions, and dividing by 5 to obtain the total 
score. The reliability, validity, and responsiveness of the 
GMFM-88 scores are documented for children with   cerebral 
palsy.50 We also used the Modified Ashworth Scale51 to 
measure spasticity in our spastic patients. The GMFM-88 and 
Modified Ashworth Scale were performed before commenc-
ing the treatment and after two months of treatment.
intervention
All patients received physical rehabilitation, which was car-
ried out for 45 minutes per day, five days per week, for two 
months. The therapy basically involved psychomotor and 
postural re-education based on neurodevelopmental reactions, 
phases, and processes (ie, neurodevelopmental therapy), and 
its contents were adapted to the specific needs of each patient, 
depending on the initial clinical assessment. In general, the 
treatment was aimed at normalizing muscle tone and improv-
ing normal postural reactions, postural   control of head and 
trunk, balance, upper limb motor function, and mobility.
To avoid any kind of bias, each therapist was assigned to 
treat children having cerebral palsy with or without growth 
hormone deficiency, without knowing their growth hor-
mone status. The Modified Ashworth scale of spasticity was 
  analyzed by one of the physiotherapists who did not know 
the growth hormone status of the patient he was examining. 
Both groups of patients received the same type and duration 
of physical rehabilitation.
Data analysis
Pre- and post-treatment data from the GMFM-88 were 
compared using a nonparametric test for two related samples 
(Wilcoxon signed-rank test and Mann-Whitney U test). 
Data from the Modified Ashworth Scale were analyzed 
descriptively.
Table 1 Main characteristics of control group patients
Patient Age 
(years)
Gender CP cause Radiologic findings Motor 
impairment
GMFCS 
level
1 4.25 M Postsurgical iatrogenic injury intense diffuse cerebral edema Flaccid TP V
2 4.5 F Perinatal hypoxia PVL spastic TP V
3 5.75 M Perinatal hypoxia Multiple hemorrhagic lesions in PV zone spastic TP V
4 9 F Perinatal hypoxia Multiple hemorrhagic lesions in PV zone Dystonic TP V
5 4.5 F Prenatal hypoxia PVL spastic TP V
6 4 M Prematurity PVL spastic TP V
7 4.5 M Prematurity PVL spastic TP V
8 4.5 F Perinatal hypoxia PVL Dystonic TP V
9 7.5 M Prematurity PVL spastic TP iV
10 10.5 F Postsurgical iatrogenic injury Diffuse cerebral edema Dystonic TP V
Abbreviations: F, female; GMFCS, Gross Motor Function Classification System; M, male; CP, cerebral palsy; PV, periventricular; PVL, periventricular leucomalacia;   
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Results
In the study group, combined treatment using rhGH and 
physical rehabilitation led to significant improvements in 
dimension A (lying and rolling, P , 0.02), dimension B 
(sitting, P , 0.02), dimension C (crawling and kneeling, 
P , 0.02), and the total score of the GMFM-88 (P , 0.01); 
dimension D (standing) and dimension E (walking, running, 
and jumping) did not increase (Figure 1B and Table 3). 
Moreover, four of five spastic patients showed a reduction in 
their spasticity as measured by the Modified Ashworth Scale 
(Table 4).   However, no significant changes were observed 
in any of these dimensions in the control group, although 
the total score significantly increased in these children (Fig-
ure 1A and Table 3), and their spasticity was not improved 
(data not shown).
The differences between the improvements achieved at 
the end of the two-month treatment period for both groups 
are shown in Figure 2 and Table 3. Clearly, as these data 
show, children with cerebral palsy and growth hormone 
deficiency achieved significant improvements in dimensions 
A, B, and C, and in total score than the control children with 
cerebral palsy.
Growth hormone administration did not produce any 
secondary clinical effects. Plasma IGF-1 levels were not 
significantly different between the two groups of children at 
the end of the treatment period, and plasma cholesterol levels 
decreased significantly (P , 0.05) in children with cerebral 
palsy and growth hormone deficiency.
Discussion
Our results show that combined treatment using rhGH and 
physical rehabilitation leads to significant improvements 
in gross motor functions, including lying, rolling, sitting, 
crawling, and kneeling. All this tasks are contained in the 
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Figure 1 Clinical data from the gMFM-88.
Notes: A) Control group. B) study group; “A”, “B”, “C”, “D” and “e” in the horizontal axis are the different dimensions of the gMFM-88 and “TOTAL” is the total score 
of test. We show pre-treatment (white bars) and post-treatment (grey bars) means and standard errors for each specific assessment. Statistical significance was calculated 
from data obtained in the gMFM-88 before treatment and after 2 months of it (Wilcoxon signed-rank test) (*P , 0.05, **P , 0.02 and *** P , 0.01).
Table 2 Main characteristics of study group patients
Patient Age 
(years)
Sex CP cause Radiologic findings Motor 
impairment
GMFCS 
level
1 4.5 F Perinatal hypoxia Multiple hemorrhagic lesions in the 
thalamus, basal ganglia, and PV region
Dystonic TP V
2 4.5 M Prematurity PVL, nodular morphology due to PO 
intraparenchymal hematomas
spastic TP V
3 4 M Post-surgical iatrogenic injury  Decreased activity and volume in PO 
cortex, bilateral PO ischemia, diffuse 
cerebral edema 
Flaccid TP V
4 9.8 M Perinatal hypoxia PVL Dystonic TP iV
5 6 F Prenatal hypoxia PVL Dystonic TP V
6 4 F Prematurity;  PVL spastic TP V
7 4.2 M Perinatal hypoxia Multicystic encephalopathy spastic TP V
8 4.5 F Perinatal hypoxia Less differentiation of structures, intense 
diffuse cerebral edema
spastic TP V
9 10.5 F Prenatal ischemia Ulegyria spastic TP iV
10 4.3 F Perinatal hypoxia PVL, corpus callosum hypoplasia Dystonic TP V
Abbreviations: F, female; GMFCS, Gross Motor Function Classification System; M, male; CP, cerebral palsy; PV, periventricular; PVL, periventricular leucomalacia; PO, 
parieto-occipital; TP, tetraplegia.Therapeutics and Clinical Risk Management 2010:6 submit your manuscript | www.dovepress.com
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normal ontogeny of human movement, and are important 
to be able to perform daily activities. However, other gross 
motor functioning, such as standing, walking, running, and 
jumping did not improve. This could be due to the brief 
duration of treatment and the subjects’ high level in the 
Gross Motor Function Classification System, such that 
they were not able to perform more complex motor tasks. 
Future studies with larger populations and a longer duration 
of treatment may be able to demonstrate differences in all 
motor functions tested.
Spasticity is defined as resistance to passive movement 
of the joints and is a key component of the so-called upper 
motor neuron syndrome.52 Spasticity, in its broadest clinical 
sense, has been linked to various motoneuronal,53 spinal,54 
and supraspinal52,55 pathophysiologic phenomena. Thus, we 
can assume that the reduction in post-treatment spasticity in 
four of five spastic patients could be related to the efficacy 
of the treatment used to achieve normalization of the balance 
of supraspinal inhibitory and excitatory signals,52,55 of the 
secondary structural and functional changes that occur at 
cellular level in the spinal cord itself below the level of the 
injury,54 and/or of the voltage-dependent persistent intrinsic 
motoneuronal inflows.53
The new physiotherapy concept, including whole body 
vibration, physiotherapy, resistance training, and   treadmill 
training, without drug treatment for six months, had a 
  significant and positive effect on bone mineral density, 
muscle force, and gross motor function in bilaterally 
spastic children with cerebral palsy.56 However, a system-
atic review did not find a statistically significant effect of 
Table 3 Results obtained from the gMFM-88
GMFM-88 Group Pretreatment 
mean score 
(SD)
Post-treatment 
mean score 
(SD)
Intragroup 
significance 
(Wilcoxon)
Improvement 
mean relative 
to baseline (%)
Group’s mean 
rank (Mann- 
Whitney) 
Intergroup 
improvement 
significance 
(Mann- 
Whitney)
Dimension A Control 40.39 (36.88) 41.17 (36.98) ns 5.5 6.9 0.004***
study 38.82 (37.63) 71.76 (29.53) 0.012** 222.79 14.1
Dimension B Control 13.16 (12.84) 13.66 (12.51) ns 15 6.8 0.002***
study 12 (13.46) 29 (22.67) 0.012** 13535.48 14.2
Dimension C Control 9.52 (13.6) 10.23 (13.51) ns 15 6.75 0.002***
study 6.9 (11.41) 20.71 (19.95) 0.012** 33457.5 14.25
Dimension D Control 2.05 (2.91) 3.07 (5.09) ns 20 11.55 ns
study 1.53 (2.75) 6.92 (13.83) ns 15426.28 9.45
Dimension e Control 1.25 (2.81) 1.52 (3.61) ns 0 11.5 ns
study 1.25 (2.81) 2.77 (6) ns 33.3 9.5
Total score Control 13.27 (12.18) 13.93 (12.12) 0.043* 10.24 14.8 0.001***
study 12.10 (12.25) 26.23 (16.1) 0.005*** 218.72 6.2
Notes: The different dimensions involved in the GMFM-88 are shown in the first column. The fifth column shows the statistical significance from data obtained in the 
gMFM-88 before treatment compared with that two months after commencing it (Wilcoxon signed-rank test). The seventh and eighth columns show the group’s mean 
rank and the statistical significance from the improvement mean relative to baseline (%) (sixth column), comparing each group with the other (Mann-Whitney U). *P , 0.05;   
**P , 0.02; ***P , 0.01. 
Abbreviations: GMFM-88, gross motor function measure; SD, standard deviation; ns, not significant.
Table 4 Results obtained from the modified ashworth scale in 
spastic patients from the study group
Patient Pretreatment Post-treatment
2 2 1+
6 3 1+
7 4 3
8 4 3
9 1+ 1+
0
ABCDE Total
*** *** *** ***
2
4
6
8
10
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14
16
Control group
Study group
Figure 2 study group improvements compared with control group improvements 
Notes: “A”, “B”, “C”, “D” and “e” in the horizontal axis are the different dimensions 
of the gMFM-88 and “TOTAL” is the total score of tet test; we show the group’s 
mean rank from Mann-Whitney U for control (white bars) and study (grey bars) 
groups. Statistcal significance was calculated from the percentage of improvement 
over baseline for each of the dimensions evaluated in the gMFM-88, comparing 
groups with each other (Mann-Whitney U) (***P , 0.01).Therapeutics and Clinical Risk Management 2010:6 submit your manuscript | www.dovepress.com
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  partial   bodyweight-supported treadmill training in children 
with cerebral palsy, despite improvements in gross motor 
  function.57 In a review of randomized controlled trials on 
physical therapy interventions in children with cerebral 
palsy, it was shown that some methods (such as neurodevel-
opmental therapy) were moderately effective in improving 
motor function in the upper extremities, walking speed, and 
stride amplitude. However, conflicting evidence was found 
for the effect of strength training on gross motor function.58 
Similarly, a meta-analysis of randomized trials demon-
strated that muscle strengthening had a small statistically 
significant, but not clinically meaningful, effect on gross 
motor function.59
On the other hand, some studies have described the effects 
of growth hormone replacement in children with cerebral 
palsy. However, most of them have only reported growth data 
and have not assessed any possible functional recovery.6,7,60
To our knowledge, this study is the first to demonstrate 
the positive effects of growth hormone administration in 
the recovery of some motor functions in children with 
cerebral palsy. Despite the fact that these were observed 
in children with cerebral palsy and growth hormone 
  deficiency, because plasma IGF-1 values were similar in 
both groups at the end of the treatment period, it seems 
clear that exogenous   administration of growth hormone 
was responsible for the effects observed. According to 
plasma IGF values, growth hormone status was similar 
in both groups at the end of the treatment period. In this 
regard, exercise is known to be a powerful stimulus for 
endogenous growth hormone release, and it has been 
demonstrated that inhibiting PI3-Akt   signaling, one of 
the pathways by which growth hormone acts,42 blocks 
exercise-mediated enhancement of adult   neurogenesis 
and synaptic plasticity in rats.61 This may explain the 
lack of   positive effects obtained in   children undergoing 
  exhaustive daily physical work, perhaps because possible 
growth   hormone deficiency has not been determined or 
treated. On the other hand, it has been recently demon-
strated that   exogenous growth hormone administration 
induces strong cellular proliferation in rodents with 
growth hormone deficiency.62 The data observed in our 
study   support our hypothesis about the effects of growth 
hormone administration.
Thus, we conclude that combined therapy involving 
growth hormone replacement and physical rehabilitation is 
a useful therapeutic approach in the recovery of gross motor 
function in children with cerebral palsy and growth hormone 
deficiency. We are now carrying out larger and longer studies 
that will allow us to understand more precisely the effects of 
hormone treatment on children with cerebral palsy, aimed 
at improving both endocrine and neurologic disorders in 
children with cerebral palsy with or without growth hormone 
deficiency.
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